OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost Acquires 100,000 Shares

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost acquired 100,000 shares of OPKO Health stock in a transaction on Thursday, November 14th. The shares were bought at an average cost of $1.62 per share, for a total transaction of $162,000.00. Following the completion of the purchase, the chief executive officer now directly owns 211,612,405 shares of the company’s stock, valued at $342,812,096.10. The trade was a 0.05 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Friday, November 8th, Phillip Md Et Al Frost bought 280,183 shares of OPKO Health stock. The shares were acquired at an average price of $1.50 per share, with a total value of $420,274.50.

OPKO Health Price Performance

OPKO Health stock traded up $0.02 during midday trading on Thursday, reaching $1.62. The company had a trading volume of 5,502,989 shares, compared to its average volume of 6,965,010. The company has a market capitalization of $1.11 billion, a P/E ratio of -8.42 and a beta of 1.65. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. OPKO Health, Inc. has a 12-month low of $0.85 and a 12-month high of $1.75. The firm’s fifty day simple moving average is $1.51 and its 200-day simple moving average is $1.43.

Analysts Set New Price Targets

A number of brokerages recently issued reports on OPK. StockNews.com upgraded OPKO Health to a “sell” rating in a report on Saturday, July 27th. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price target on shares of OPKO Health in a research report on Thursday, September 26th. Barrington Research reissued an “outperform” rating and issued a $2.25 target price on shares of OPKO Health in a research report on Friday, November 8th. Finally, Piper Sandler reissued an “overweight” rating and issued a $3.00 target price on shares of OPKO Health in a research report on Tuesday, September 17th.

Institutional Trading of OPKO Health

Several institutional investors have recently made changes to their positions in the company. Rubric Capital Management LP raised its position in OPKO Health by 9.6% in the third quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock valued at $72,573,000 after purchasing an additional 4,284,336 shares during the period. Assenagon Asset Management S.A. raised its position in OPKO Health by 142.5% in the third quarter. Assenagon Asset Management S.A. now owns 1,490,992 shares of the biotechnology company’s stock valued at $2,227,000 after purchasing an additional 876,272 shares during the period. Y.D. More Investments Ltd purchased a new stake in OPKO Health in the second quarter valued at approximately $1,840,000. AWM Investment Company Inc. raised its position in OPKO Health by 18.2% in the first quarter. AWM Investment Company Inc. now owns 1,300,000 shares of the biotechnology company’s stock valued at $1,560,000 after purchasing an additional 200,000 shares during the period. Finally, PFG Investments LLC raised its position in OPKO Health by 10.4% in the third quarter. PFG Investments LLC now owns 1,061,090 shares of the biotechnology company’s stock valued at $1,581,000 after purchasing an additional 100,125 shares during the period. Hedge funds and other institutional investors own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.